Difference between revisions of "Dosulepine-imipramine"

From Psychiatrienet
Jump to: navigation, search
Line 10: Line 10:
 
| info =
 
| info =
 
* {{TCAantichol}}
 
* {{TCAantichol}}
 +
{{review}}
 
}}
 
}}

Revision as of 16:57, 28 October 2015

dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin
Imipramine
Type Antidepressant
Group TCA
links
Medscape Imipramine
PubChem 3696
PubMed Imipramine
Kompas (Dutch) Imipramine
Wikipedia Imipramine

Switch medication from dosulepine to imipramine.[1] [2]

Nietinrijdenbord.png Stop dosulepine
  • Gradually reduce dosage of dosulepine to a maximum of 50 mg/day.
  • When a dosage of 50 mg/day is reached, stop administration.
Eenrichtingbord.png Start imipramine
  • No wash-out period is needed.
  • Start administration of imipramine the next day in a normal dosage of 50-100 mg/day.
Infobord.png More information
  • Both drugs are a TCA with anticholinergic properties, so a switch to a relatively high starting dose can be made.
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.